Cellectis ALCLS.PA · EUR

Its shares trade on Euronext Paris under the ticker ALCLS.PA. It has been listed since 6 February 2007. In the fiscal year to 31 December 2025, it reported revenue of $75.9m and a net loss of $70.3m. At that date it held total assets of $324.7m and shareholders' equity of $75.9m.

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Jean-Pierre GarnierNon-Executive Independent Chairman of the Board$106,626
• Dr. Andre ChoulikaChief Executive Officer, Co-Founder, Director, since 2000$937,539
• Dr. David SourdiveDeputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director, since 2000$593,156
• Mr. Arthur StrilChief Financial Officer and Chief Business Officer
• Ms. Kyung Nam-WortmanChief Human Resources Officer, Executive Vice President
• Dr. Steven DoaresSenior Vice President - US Manufacturing
• Dr. Philippe DuchateauChief Scientific Officer
• Mr. Stephan ReynierChief Regulatory and Pharmaceutical Compliance Officer, since 2022
• Ms. Marie-Bleuenn TerrierGeneral Counsel
• Dr. Adrian KilcoyneChief Medical Officer
• Mr. Andre MullerDirector
• Mr. Marc DunoyerNon-Executive Director

Overall

70

Environment

78

Social

99

Governance

31

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.